Enasidenib for Acute Myeloid Leukemia

"Initially researched in 2011 by Memorial Sloan Kettering Cancer Center, enasidenib has since seen 128 trials to completion. Currently, 53 active studies are recruiting patients across the nation - primarily in Syracuse, New york."

"Enasidenib is frequently deployed in invasive operations, but has also been found to be effective for treating hypertensive disease, skin disinfection therapy and benign prostatic hyperplasia (BPH)."

"This clinical trial is recruiting 10 participants aged between 24 months and 18 years old with myeloid leukemia. Furthermore, they must have experienced second or subsequent relapse after either chemotherapy treatment or hematopoietic stem cell transplant (HSCT); be refractory to >=2 induction therapy attempts; not received any re-induction therapies for this particular relapse; Karnofsky performance score of >50% if over 16 year olds and Lansky > 50% if younger than that age bracket; and ambulatory ability in some capacity, including wheelchair use."

"Our team at Power rates the safety of Enasidenib as a 2 due to its Phase 2 status, which indicates prior clinical data proving safety but no evidence on efficacy."

"The main evaluation metric of this trial, measured over a year-long period post last dose, is the area under enasidenib's plasma concentration curve. Other key statistics include median time to remission and death with 95% confidence intervals as well as frequency (%) of patients that have achieved at least partial response per dosage level."

"Prospective participants of this research must be between the age span of 2 years to 18 years. Clinical trials for those younger than 18 number 448 and 1220 studies are available for patients above 65."

"Unfortunately, this particular medical study is no longer recruiting patients. Initially posted on March 30th 2020 and last updated September 1st 2022, the trial has reached its desired enrolment count. However, there are still 1466 trials actively searching for participants with myeloid leukemia and 53 studies looking to recruit people taking Enasidenib."

"Patients are being accepted at the State University of New york Upstate Medical University, Arkansas Children's Hospital and Riley Hospital for Children, to name a few among 18 other trial sites."

"According to the data published on clinicaltrials.gov, this medical trial is not currently accepting applications as its last update was made in September 1st 2022. Nonetheless, there are 1519 other trials actively recruiting individuals for participation at present."